Key Takeaways
- • Jeito Capital closed its second fund at €1 billion ($1.2 billion), exceeding its target and solidifying its position as a dedicated biopharmaceutical private equity investor.
- • The fund focuses on mid- and late-stage European biopharmaceutical companies, targeting clinical development and market access opportunities across the region.
- • The oversubscribed close reflects strong institutional investor confidence in Jeito's sector-focused strategy and track record in the biopharma space.
- • The capital deployment will support European biopharma companies navigating regulatory pathways and commercialization phases of drug development.
Summary
Jeito Capital announced the closing of its second fund on April 8, 2026, raising more than €1 billion ($1.2 billion) from institutional investors. The fund exceeded its target, marking a successful oversubscribed close for the biopharmaceutical-focused private equity firm.
The fund targets mid- and late-stage European biopharmaceutical companies, with capital dedicated to advancing clinical development and supporting market access initiatives. This strategic positioning allows Jeito to focus on companies in critical stages of drug development where significant capital and operational expertise are required to navigate regulatory approval processes and commercialization pathways.
The successful fundraising demonstrates sustained institutional appetite for specialized private equity strategies in the life sciences sector. Investors continue to recognize the value of sector-focused managers with deep expertise in biopharmaceutical development, regulatory dynamics, and market entry strategies specific to European markets. The oversubscribed nature of the fund indicates strong confidence in Jeito's operational track record and ability to generate returns in a capital-intensive, high-risk industry characterized by complex clinical and regulatory requirements.
The fund targets mid- and late-stage European biopharmaceutical companies, with capital dedicated to advancing clinical development and supporting market access initiatives. This strategic positioning allows Jeito to focus on companies in critical stages of drug development where significant capital and operational expertise are required to navigate regulatory approval processes and commercialization pathways.
The successful fundraising demonstrates sustained institutional appetite for specialized private equity strategies in the life sciences sector. Investors continue to recognize the value of sector-focused managers with deep expertise in biopharmaceutical development, regulatory dynamics, and market entry strategies specific to European markets. The oversubscribed nature of the fund indicates strong confidence in Jeito's operational track record and ability to generate returns in a capital-intensive, high-risk industry characterized by complex clinical and regulatory requirements.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.